Speedier drug approvals hit slowdown as FDA faces scrutiny

Dec 6, 2022, 10:01 PM | Updated: 10:31 pm
FILE - A sign in front of the Food and Drug Administration building is seen on Dec. 10, 2020, in Si...

FILE - A sign in front of the Food and Drug Administration building is seen on Dec. 10, 2020, in Silver Spring, Md. Expedited drug approvals slowed in 2022, as the FDA's controversial accelerated pathway came under new scrutiny from Congress, government watchdogs and some of the agency’s own leaders. With less than a month remaining in the year, the agency’s drug center has granted 10 accelerated approvals — fewer than the tally in each of the last five years, when use of the program reached all-time highs. (AP Photo/Manuel Balce Ceneta, File)

(AP Photo/Manuel Balce Ceneta, File)

WASHINGTON (AP) — Expedited drug approvals slowed this year as the Food and Drug Administration’s controversial accelerated pathway came under new scrutiny from Congress, government watchdogs and some of the agency’s own leaders.

With less than a month remaining in the year, the FDA’s drug center has granted 10 accelerated approvals — fewer than the tally in each of the last five years, when use of the program reached all-time highs.

The program allows drugs to launch in the U.S. based on promising early results, before they are proven to benefit patients.

Academics have long complained that the practice has resulted in a glut of expensive, unproven medications, particularly for cancer. But last year’s accelerated approval of a much-debated Alzheimer’s drug touched off a new round of criticism, including investigations of FDA’s decision making by federal inspectors and Congress.

A recent FDA hearing aimed at revoking approval from an unproven preterm birth drug further underscored the program’s shortcomings. FDA has been trying to get the drug, Makena, off the market for more than two years, because a follow-up study showed it didn’t benefit infants or mothers. The manufacturer has refused to cooperate.

Amid the latest controversy, FDA leaders have taken unprecedented steps suggesting a tougher stance on accelerated approval: nudging drugmakers to remove a growing list of unproven uses for drugs and asking Congress for new powers to expedite removals when companies balk.

Dr. Reshma Ramachandran, a Yale University researcher who supports congressional reforms, believes the recent scrutiny of the accelerated approval process “definitely led to them pausing and taking a different path.” Still, Ramachandran and other critics say it’s too early to tell if FDA’s recent actions reflect a longer-term policy shift.

An FDA spokeswoman said the agency’s posture on accelerated approval “has remained consistent and the agency is committed to ensuring the integrity of the program.” She added that FDA is using “every authority at our disposal” to make sure drugmakers quickly conduct confirmatory studies after approval.

Launched in 1992, the accelerated approval program is credited with speeding the availability of early breakthroughs for HIV and cancer. About 300 drug approvals have been made that way, nearly half of them in the last five years.

But researchers and government watchdogs have chronicled problems with FDA’s oversight, including delays in quickly removing drugs with failed or missing confirmatory studies. Federal inspectors recently found that 40% of accelerated approvals had incomplete confirmation studies.

The picture is beginning to change. In less than two years, the FDA has successfully called on drugmakers to remove more than 20 approvals from accelerated drugs — mainly cancer therapies — that failed to show a benefit. That’s more than half the withdrawals in the program’s history.

FDA’s cancer chief, Dr. Rick Pazdur, has referred to this effort of clawing back approvals as his “jihad.”

Several drugmakers recently declined FDA requests to voluntarily pull their drugs. That’s raised the specter of more long, onerous public hearings to force removal, a process Pazdur called “a nightmare.”

The ability to require drugmakers to have their studies underway before approval is one part of legislation that congressional lawmakers hope to attach to a massive, end-of-the-year spending bill. If passed, it would be the biggest overhaul in accelerated approval’s 30-year history.

“We need more teeth in terms of getting the confirmatory trials started before accelerated approval,” FDA Commissioner Robert Califf said at a recent cancer conference. “Once approval occurs it’s very difficult to hold back the marketeers.”

FDA regulators are already testing out the approach. Increasingly, the agency is telling drugmakers they must have their confirmation studies underway before approval.

“We know the FDA has raised the bar for accelerated approval, and so that’s why we’re seeking additional clarity on their position,” Mike Sherman, CEO of startup Chimerix, told investors on a recent call discussing the company’s plans for an upcoming cancer drug.

A higher bar could spell trouble for smaller drugmakers, who often rely on accelerated approval to gain a market foothold before raising additional funds.

To be sure, FDA approval trends are impacted by a variety of forces. The agency’s overall tally of novel drugs is down markedly this year at about 30, compared with 50 last year. And even the recent peak in use of the accelerated pathway — 45 approvals in 2020 — reflected several trends.

Drugmakers have been aggressively pursuing a new class of “immunotherapies” that help the body recognize and attack cancer. The FDA has granted more than 80 uses for those drugs since 2015, pushing up annual accelerated approval tallies.

Additionally, COVID-19 pandemic disruptions forced some drugmakers to cut short their research plans, asking FDA for accelerated approval based on partially completed studies, instead of a full results.

“There was a lot of reinterpretation of the FDA rules to make sure those companies could proceed, otherwise they would have lost billions of dollars,” said Sam Kay, a consultant with Clarivate, which advises pharmaceutical companies.

It’s a reminder of how much flexibility the FDA has.

Many of the reforms pending in Congress “are things the FDA could do now,” notes Ramachandran.

“I think having Congress do it gives them the cover and blessing to carry forward with what they want to do,” she said.

___

Follow Matthew Perrone on Twitter: @AP_FDAwriter

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

AP

FILE - Ozzy Osbourne arrives at the 62nd annual Grammy Awards at the Staples Center on Jan. 26, 202...
Associated Press

Ozzy Osbourne cancels 2023 European tour dates, cites injury

Hard rock legend Ozzy Osbourne announced the cancellation of his 2023 tour dates in the U.K. and continental Europe. Osbourne issued a statement early Wednesday saying damage to his spine suffered in an accident four years ago will prevent him from touring. “I am honestly humbled by the way you’ve all patiently held onto your […]
2 hours ago
A view of a placard as ambulance workers stand on the picket line outside Leeds Ambulance Station i...
Associated Press

Day of disruption in UK as thousands join mass walkout

LONDON (AP) — Thousands of schools in the U.K. are closing some or all of their classrooms, train services will be paralyzed and delays are expected at airports Wednesday in what’s shaping up to be the biggest day of industrial action Britain has seen in more than a decade, as unions step up pressure on […]
2 hours ago
Currency traders watch computer monitors at a foreign exchange dealing room in Seoul, South Korea, ...
Associated Press

Global stocks higher ahead of Fed rate decision

BEIJING (AP) — Global stocks rose Wednesday while Wall Street futures declined ahead of what traders hope will be the last Federal Reserve interest rate hike for some time. London and Frankfurt opened hire. Shanghai, Tokyo and Hong Kong advanced. Oil prices gained. Traders expect the Fed to raise its benchmark lending rate but hope […]
1 day ago
FILE - Abortion-rights protesters project messages to a building during an event sponsored by Susan...
Associated Press

Anti-abortion activists aim to sway GOP White House hopefuls

CHICAGO (AP) — Emboldened anti-abortion activists are looking to the 2024 presidential election as an opportunity to solidify their influence over the Republican Party. Susan B. Anthony Pro-Life America, the most influential group in the anti-abortion movement, is telling each potential GOP presidential hopeful that to win its backing — or avoid being a target […]
1 day ago
FILE - Federal Reserve Chair Jerome Powell speaks during a news conference Wednesday, Dec. 14, 2022...
Associated Press

Powell likely to stress Fed’s inflation fight far from over

WASHINGTON (AP) — Inflation is cooling, and parts of the economy appear to be weakening. But Chair Jerome Powell is likely Wednesday to underscore that the Federal Reserve’s primary focus remains the need to fight surging prices with still-higher interest rates. With financial markets anticipating that the Fed will stop raising rates soon and possibly […]
1 day ago
Containers are seen at the country's largest port, in Busan, South Korea, on Jan. 10, 2023. South K...
Associated Press

South Korea logs record trade deficit as tech demand falls

SEOUL, South Korea (AP) — South Korea logged its biggest monthly trade deficit ever, at $12.7 billion in January, as exports of computer chips and other high-tech items sank and costs for importing oil and gas surged, the trade ministry said Wednesday. The growing shortfall underscored how Russia’s war on Ukraine is straining the global […]
1 day ago

Sponsored Articles

...
Day & Night Air Conditioning, Heating and Plumbing

Company looking for oldest air conditioner and wants to reward homeowner with new one

Does your air conditioner make weird noises or a burning smell when it starts? If so, you may be due for an AC unit replacement.
(Desert Institute for Spine Care photo)...
DESERT INSTITUTE FOR SPINE CARE

Why DISC is world renowned for back and neck pain treatments

Fifty percent of Americans and 90% of people at least 50 years old have some level of degenerative disc disease.
...
Quantum Fiber

Stream 4K and more with powerful, high-speed fiber internet

Picking which streaming services to subscribe to are difficult choices, and there is no room for internet that cannot handle increased demands.
Speedier drug approvals hit slowdown as FDA faces scrutiny